195 related articles for article (PubMed ID: 16002679)
1. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G
J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679
[TBL] [Abstract][Full Text] [Related]
2. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
Correale P; Botta C; Cusi MG; Del Vecchio MT; De Santi MM; Gori Savellini G; Bestoso E; Apollinari S; Mannucci S; Marra M; Abbruzzese A; Aquino A; Turriziani M; Bonmassar L; Caraglia M; Tagliaferri P
Int J Cancer; 2012 Apr; 130(7):1577-89. PubMed ID: 21618510
[TBL] [Abstract][Full Text] [Related]
5. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Correale P; Del Vecchio MT; Di Genova G; Savellini GG; La Placa M; Terrosi C; Vestri M; Urso R; Lemonnier F; Aquino A; Bonmassar E; Giorgi G; Francini G; Cusi MG
J Natl Cancer Inst; 2005 Oct; 97(19):1437-45. PubMed ID: 16204693
[TBL] [Abstract][Full Text] [Related]
6. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
Correale P; Aquino A; Giuliani A; Pellegrini M; Micheli L; Cusi MG; Nencini C; Petrioli R; Prete SP; De Vecchis L; Turriziani M; Giorgi G; Bonmassar E; Francini G
Int J Cancer; 2003 Apr; 104(4):437-45. PubMed ID: 12584740
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
Dauer M; Herten J; Bauer C; Renner F; Schad K; Schnurr M; Endres S; Eigler A
J Immunother; 2005; 28(4):332-42. PubMed ID: 16000951
[TBL] [Abstract][Full Text] [Related]
8. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
Correale P; Sabatino M; Cusi MG; Micheli L; Nencini C; Pozzessere D; Petrioli R; Aquino A; De Vecchis L; Turriziani M; Prete SP; Sanguedolce R; Rausa L; Giorgi G; Francini G
J Chemother; 2001 Oct; 13(5):519-26. PubMed ID: 11760216
[TBL] [Abstract][Full Text] [Related]
9. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P
J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
11. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
14. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P; Tagliaferri P; Fioravanti A; Del Vecchio MT; Remondo C; Montagnani F; Rotundo MS; Ginanneschi C; Martellucci I; Francini E; Cusi MG; Tassone P; Francini G
Clin Cancer Res; 2008 Jul; 14(13):4192-9. PubMed ID: 18593999
[TBL] [Abstract][Full Text] [Related]
15. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Correale P; Fioravanti A; Bertoldi I; Montagnani F; Miracco C; Francini G
J Chemother; 2008 Apr; 20(2):278-81. PubMed ID: 18467257
[TBL] [Abstract][Full Text] [Related]
17. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
Lesterhuis WJ; de Vries IJ; Aarntzen EA; de Boer A; Scharenborg NM; van de Rakt M; van Spronsen DJ; Preijers FW; Figdor CG; Adema GJ; Punt CJ
Br J Cancer; 2010 Oct; 103(9):1415-21. PubMed ID: 20924373
[TBL] [Abstract][Full Text] [Related]
18. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
[TBL] [Abstract][Full Text] [Related]
19. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Bergmann-Leitner ES; Abrams SI
J Immunol; 2000 May; 164(9):4941-54. PubMed ID: 10779805
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
Liu WM; Fowler DW; Smith P; Dalgleish AG
Br J Cancer; 2010 Jan; 102(1):115-23. PubMed ID: 19997099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
